• Home
  • Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.

Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.

Author List
Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group
Publication
Annals of surgical oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/526293713
Publication Year
2024
PubMed ID
38980586
Publication Title
Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.